2022-04-252022-04-252012-06Ersoy, A. ve Koca, N. (2012). "Everolimus-induced lymphedema in a renal transplant recipient: a case report". Experimental and Clinical Transplantation, 10(3), 296-298.1304-0855https://doi.org/10.6002/ect.2011.0139http://www.ectrx.org/forms/ectrxcontentshow.php?doi_id=10.6002/ect.2011.0139http://hdl.handle.net/11452/26018The mammalian target of rapamycin inhibitors is commonly preferred for solid organs for transplantation. Although these drugs have various adverse effects, sirolimus-related lymphedema has been rarely reported. We report a case of lymphedema related to everolimus after a kidney transplant. A 60-year-old woman successfully received a deceased-donor kidney. Everolimus was added to the treatment in postoperative month 3 owing to other immunosuppressive drugs' adverse effects. Edema occurred first on her feet in the first year after the transplant. During 3 months' follow-up, with no immunosuppressive adjustment, the edema progressed. Diagnosis of lymphedema was established. Several weeks after discontinuing everolimus, the patient's lymphedema began to resolve itself and completely disappeared in 3 months. The mammalian target of rapamycin inhibitors rarely causes lymphedema by inhibiting different subtypes of vascular endothelial growth factors, which results in impaired lymphangiogenesis. While there are few reports about sirolimus-related lymphedema, this case represents the first everolimus-related case of lymphedema. Further studies are warranted to explain the underlying mechanisms.eninfo:eu-repo/semantics/openAccessTransplantationEdemaImmunosuppressionKidney transplantMtor inhibitorsComplicationSirolimusLymphangiogenesisInhibitionTherapyVegfFemaleFollow-up studiesGraft rejectionHumansImmunosuppressive agentsKidney failure, chronicKidney transplantationLymphedemaLymphoscintigraphyMiddle agedSirolimusTime factorsTransplantationTreatment outcomeWithholding treatmentArticle0003053815000172-s2.0-8486263047829629810322631070TransplantationEverolimus; Calcineurin Inhibitors; Kidney TransplantationBasiliximabCreatinineCyclosporinEverolimusGlucoseMycophenolic acid 2 morpholinoethyl esterSteroidTacrolimusAdultArticleCase reportDrug withdrawalFemaleFoot edemaGraft recipientHumanHyperglycemiaImmunosuppressive treatmentKidney failureKidney transplantationLeukopeniaLymphedemaLymphoscintigraphyPostoperative careThrombocytopenia